会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 46. 发明专利
    • Positioning device for proximal bone chip of a lower jawbone in sagittal split ramus osteotomy
    • 用于劈裂腰椎间盘突起的下颌骨的替代骨块的定位装置
    • JP2014155634A
    • 2014-08-28
    • JP2013028700
    • 2013-02-18
    • Toho Univ Foundation学校法人東邦大学
    • KUDO TAIICHI
    • A61B17/56
    • PROBLEM TO BE SOLVED: To eliminate disadvantages of a conventional method of repositioning a proximal bone chip of a lower jawbone.SOLUTION: A positioning device includes: a bone gripping element 1 for gripping a proximal bone chip 4 of a lower jawbone; a positioning element 2 for gripping a reference point P2 set in an upper jaw; and a connection element 3 for fixing the positioning element 2 so as to adjust the position with respect to the bone gripping element 1. In a state that the bone gripping element 1 grips the proximal bone chip 4 and the positioning element 2 grips the reference point P2, the attitude of the positioning element 2 with respect to the bone gripping element 1 is fixed so that a three-dimensional positional relationship between the bone gripping element 1 and the positioning element 2 is recorded.
    • 要解决的问题:消除重新定位下颚骨近端骨芯片的常规方法的缺点。解决方案:定位装置包括:用于夹持下颚骨近端骨块4的骨抓握元件1; 用于夹持设置在上颚中的参考点P2的定位元件2; 以及用于固定定位元件2以便调节相对于骨抓持元件1的位置的连接元件3.在骨抓握元件1握住近端骨芯4并且定位元件2握住参考点的状态下 P2中,定位元件2相对于骨抓握元件1的姿态被固定,从而记录骨抓握元件1和定位元件2之间的三维位置关系。
    • 49. 发明专利
    • Model of sustained atrial fibrillation and method for producing same, and method for screening atrial fibrillation inhibitor
    • 持续性椎间孔纤维化的模型及其生产方法,以及筛选ATRIAL FIBRILLATION抑制剂的方法
    • JP2012235780A
    • 2012-12-06
    • JP2012109779
    • 2012-05-11
    • Toho Univ Foundation学校法人東邦大学
    • SUGIYAMA ATSUSHI
    • A01K67/00A61K31/196A61K31/215A61K31/7012A61P9/00A61P9/06
    • PROBLEM TO BE SOLVED: To provide an antiarrhythmic and an atrial fibrillation inhibitor having excellent inhibitory action to a cardiac arrhythmias including an atrial fibrillation, having fewer side-effects, and being highly safe, a model of sustained atrial fibrillation, as well as a production method thereof, suitable to use for screening of the atrial fibrillation inhibitor, and a screening method of the atrial fibrillation inhibitor capable of screening the atrial fibrillation inhibitor efficiently and conveniently by using the model of sustained atrial fibrillation.SOLUTION: The production method of the model of sustained atrial fibrillation includes: an atrium hypertrophy expansion process for inserting an electrode catheter in an atrioventricular node region of a dog, energizing a high frequency from the electrode catheter to the atrioventricular node region to destroy the atrioventricular node, and blocking the atrioventricular conduction to hypertrophy and expand an atrium; and an atrial pacing process for pacing the hypertrophied and expanded atrium.
    • 要解决的问题:提供一种抗心律失常药物和心房颤动抑制剂,其对心律失常具有优异的抑制作用,包括心房颤动,副作用较少,并且高度安全,持续性心房颤动模型,以及 作为适用于筛选心房颤动抑制剂的制造方法,以及能够通过使用持续性心房颤动模型有效且方便地筛选心房颤动抑制剂的心房颤动抑制剂的筛选方法。 持续性房颤模型的生产方法包括:将电极导管插入狗的房室结区域的心房肥大扩张过程,将高频从电极导管通向房室结区域, 破坏房室结,并阻断房室传导至肥大并扩大心房; 以及用于起搏肥大和扩张的心房的心房起搏过程。 版权所有(C)2013,JPO&INPIT
    • 50. 发明专利
    • COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, HAVING ACTIVITY FOR INHIBITING AGGREGATION OF AMYLOID β-PROTEIN, METHOD FOR PRODUCING THE SAME, AND APPLICATION THEREOF
    • 化合物或其药学上可接受的盐,具有用于抑制淀粉样蛋白和β-葡聚糖的聚集的活性,其生产方法及其应用
    • JP2012184224A
    • 2012-09-27
    • JP2012031690
    • 2012-02-16
    • Toho Univ Foundation学校法人東邦大学
    • SUZUKI EIJIISHIGAMI AKITOYOKOYAMA YUSAKUNAKAKOSHI MASAMICHI
    • C07D307/80A61K31/343A61K31/443A61K31/506A61P25/28A61P43/00C07B61/00C07D405/04
    • PROBLEM TO BE SOLVED: To provide a new compound or a pharmacologically acceptable salt thereof, having excellent activity for inhibiting aggregation of amyloid β-protein and/or activity for dissolving the amyloid β-protein, and capable of preventing and/or treating Alzheimer-type dementia, to provide a method for producing the compounds, and to provide a medicinal composition, an amyloid β-protein aggregation inhibitor, an amyloid β-protein solubilizer and an agent for preventing or treating the Alzheimer-type dementia.SOLUTION: There is provided the compound represented by general formula (1A) or the pharmacologically acceptable salt thereof. In general formula (1A), Xs are each independently one of OR, OCOR, N(R), I, Br, Cl and F; Xs are each independently one of COR, OCOR, OCH, OH, NRand CHOH; R, R, Rand Rare each hydrogen or alkyl; Rand Rare each methyl or OR; Ris alkyl; Y, Y, Yand Yare each carbon or nitrogen; n is an integer of 0-3; m is an integer of 1-3; R, R, Rand Rmay be the same as or different from each other; Rand Rmay be the same or different; and Y, Y, Yand Ymay be the same or different.
    • 待解决的问题:提供具有优异的抑制淀粉样蛋白β-蛋白聚集的活性和/或溶解淀粉样蛋白β-蛋白的活性的新化合物或其药理学上可接受的盐,并且能够预防和/或 提供一种制备该化合物的方法,提供一种药物组合物,淀粉样蛋白β蛋白聚集抑制剂,淀粉样β蛋白增溶剂和用于预防或治疗阿尔茨海默氏型痴呆的药剂。 提供由通式(1A)表示的化合物或其药理学上可接受的盐。 在通式(1A)中,X 1 各自独立地为OR 1 之一,OCOR 2 ,N(R 3 2 ,I,Br,Cl和F; X 2 各自独立地为CO 2 R 4 5 ,OCH 3 ,OH,NR 6 和CH 2 OH; R 1 ,R 3 ,R 4 ,R 6 各自为氢或烷基; R 2 和R 5 分别为甲基或OR 7 ; R 7 是烷基; Y 1 ,Y 2 ,Y 3 ,Y 4 分别为碳或氮; n为0-3的整数; m为1-3的整数; R 1 ,R 3 ,R 4 ,R 6 可以彼此相同或不同; R 2 和R 5 可以相同或不同; 和Y 1 ,Y 2 ,Y 3 和Y 4 可能相同或不同。 版权所有(C)2012,JPO&INPIT